| Document |
Document Title |
|
WO/2024/092372A1 |
Provided is a process to obtain a target colorant from a microorganism. The process includes fermenting a culture including the microorganism and a nutrition-rich fermentation medium in a first fermentation batch to harvest a fermented b...
|
|
WO/2024/092360A1 |
Described herein are methods and antibodies useful for reducing, eliminating, or preventing infection with a bacterial or viral population in an aquatic animal. Also described herein are antigens useful for targeting by heavy chain antib...
|
|
WO/2024/096119A1 |
The present disclosure relates to providing an oral environment model of a subject, or a medium representing that model. More specifically, the present disclosure relates to a medium for culturing oral indicator bacteria using oral compo...
|
|
WO/2024/093260A1 |
Provided are a bacterial tryptophan-5-hydroxylase and use thereof. The bacterial tryptophan-5-hydroxylase comprises the amino acid sequence set forth in SEQ ID NO. 1, SEQ ID NO. 3, or SEQ ID NO. 5, or an amino acid sequence having 50% or...
|
|
WO/2024/096121A1 |
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene...
|
|
WO/2024/096123A1 |
The present disclosure relates to the prevention of transmission and/or spread within the environment and to humans when using a bacterial preparation. More specifically, the present disclosure relates to a microorganism in which at leas...
|
|
WO/2024/097396A1 |
The presently disclosed subject matter relates a single dose formulation for oral delivery of biologically active agent. In one embodiment, single dose formulation for oral delivery of biologically active agent includes a vaccine antigen...
|
|
WO/2024/095989A1 |
The present invention addresses the problem of providing: a method for selectively measuring the number of cells of a bacterium capable of activating a plasmacytoid dendritic cell (e.g., a lactic acid bacterium such as a bacterium of str...
|
|
WO/2024/097990A1 |
Recombinant yeasts bioengineered to overexpress genes for utilization of cellulosic and hemicellulosic fibers and/or produce lipid, and methods of use thereof. The yeasts are modified to express, constitutively express, or overexpress an...
|
|
WO/2024/093843A1 |
Disclosed are a disease resistance-related protein RCR1, a coding gene thereof, and use thereof. The disease resistance-related protein RCR1 provided by the present invention is a protein set forth in sequence 2. The present invention de...
|
|
WO/2024/040046A3 |
In one aspect, the disclosure relates to recombinant bacterial vectors including a gene encoding at least one antigen from Aeromonas hydrophila or tilapia lake virus, methods of making the same, vaccines incorporating the same, and metho...
|
|
WO/2024/096022A1 |
Provided is an anti-adiponectin antibody or an antibody fragment thereof in which LCDR1 includes an amino acid sequence of SEQ ID NO: 17 or 18, LCDR2 includes an amino acid sequence of SEQ ID NO: 19 or 20, LCDR3 includes an amino acid se...
|
|
WO/2024/096129A1 |
Disclosed is a biomarker for use in the prediction of the occurrence and the severity of acne vulgaris, and in the determination of the severity of acne vulgaris.
|
|
WO/2024/096122A1 |
The present disclosure provides a microbiome for the purpose of improving the response rate of an immune checkpoint inhibitor. Specifically, the present disclosure provides a microorganism wherein at least one gene among a flagella-formi...
|
|
WO/2024/050288A3 |
A microbial platform for rare earth element bioaccumulation comprises a bacterial culture, a medium comprising methanol, inorganic phosphate, and a swarf pulp, wherein the platform is selective for bioaccumulation of a rare earth element.
|
|
WO/2024/095909A1 |
A cell detachment device for detaching cells by vibrating cells provided on a culture surface of a cell culture vessel, wherein: the cell peeling device has a vibrator and a diaphragm; the vibrator, the diaphragm, an acoustic transmissio...
|
|
WO/2024/090562A1 |
Provided is a method for producing a glutamate dehydrogenase of which the coenzyme is FAD. Also provided is a FAD-dependent glutamate dehydrogenase having a specified amino acid substitution.
|
|
WO/2024/091122A1 |
The invention is directed to a method for providing a foodstuff preservative. More specifically, to a foodstuff preservative that inhibits growth of Escherichia, Salmonella and/or Listeria. The invention is further directed to a foodstuf...
|
|
WO/2024/092260A1 |
The present disclosure provides an isolated Glycomyces lithiumensis (ECO002) strain deposited at the Agricultural Research Service Culture Collection under the Accession number NRRL No. B-68190 according to the Budapest Treaty. The discl...
|
|
WO/2024/087761A1 |
The present invention relates to a method for producing a polypeptide from a recombinant fusion protein, and disclosed are a method for producing a polypeptide by means of serially combining multiple protease cleavage sites and polypepti...
|
|
WO/2024/092294A1 |
A bacterial composition for substrate inoculation to improve the fertility of the substrate comprises a predetermined concentration of at least one strain of autotrophic bacteria, wherein the autotrophic bacteria is characterised in havi...
|
|
WO/2024/086954A1 |
The invention relates to culture medium formulations that are useful for the in vitro cultivation of ectomycorrhizal fungi of the genus Ramaria. Furthermore, it discloses a method for the in vitro propagation of ectomycorrhizal fungi of ...
|
|
WO/2024/090464A1 |
Provided is a composition for the skin, the composition having, as an active ingredient, an extract obtained by fermenting and aging Aspergillus oryzae and two types of lactic acid bacteria. As a specific example, the present invention i...
|
|
WO/2024/089197A1 |
The present disclosure provides a yeast composition enriched in at least one vitamin and/or in at least one sterol that can be used to provide antioxidant activity. The yeast composition can be used to prevent or limit the oxidation of a...
|
|
WO/2024/088435A1 |
Provided is a Pseudomonas sp. having a mutant of PHA polymerase PhaC61-3. The Pseudomonas sp. is fermented to produce a novel viscous polyhydroxyalkanoate, providing a new material for the preparation of degradable products.
|
|
WO/2024/090414A1 |
The present invention addresses the problem of providing a lactic acid bacterium having high natural immunoactivation ability. The present invention also addresses the problem of providing: a natural immunoactivating agent having, as an ...
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
|
WO/2024/090415A1 |
The present invention addresses the problem of providing lactic acid bacteria having high ability to activate innate immunity. The present invention also addresses the problem of providing: an innate immunity activator containing, as an ...
|
|
WO/2024/087263A1 |
Zavarzinia compransoris capable of degrading an organophosphorus flame retardant and a use of Zavarzinia compransoris. A GDUTXIONG2 strain of Zavarzinia compransoris capable of degrading an organophosphorus flame retardant is obtained by...
|
|
WO/2024/090563A1 |
The purpose of the present invention is to provide: a nucleic acid for gene expression uses, which can amplify a conditional gene expression vector stably, can be used in a gene expression analysis in a wide variety of organism species a...
|
|
WO/2024/088386A1 |
The present application discloses the antibodies or antigen-binding fragments, and their pharmaceutical use. In particular, a monoclonal antibody according to the present application suppresses tumors, and can thus be useful as a cancer ...
|
|
WO/2024/088396A1 |
Provided are an FNR mutant and the use thereof in gene expression regulation. The mutant has an R169G and/or a G216D mutation on the amino acid sequence of the FNR, and the amino acid sequence of the FNR is as shown in SEQ ID NO: 1, or h...
|
|
WO/2024/091705A2 |
Disclosed herein are novel methods and compositions of matter to produce 3HB in acetogens by using a (S)-3-hydroxybutyryl-CoA dehydrogenase, Hbd2, responsible for endogenous 3HB production. In conjunction with the heterologous thiolase a...
|
|
WO/2024/090413A1 |
The present invention addresses the problem of providing a lactic acid bacterium having high natural immunoactivating capability. The present invention also addresses the problem of providing: a natural immunoactivator which contains, as...
|
|
WO/2024/090440A1 |
It was discovered that, by using (a) FDC in which position 397 is tryptophan, position 398 is methionine, position 440 is tyrosine, and position 189 is methionine and/or (b) FDC in which position 397 is tryptophan, position 398 is methio...
|
|
WO/2024/091686A1 |
Methods for the production of biocement utilizing diazotrophic cyanobacteria, aggregate and water where the diazotrophic cyanobacteria is present under conditions that induce microbially induced calcite precipitation (MICP).
|
|
WO/2024/090668A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising as active ingredients a Bacillus velezensis JK1 strain deposited under the accession number KCTC 14627BP and a culture broth ther...
|
|
WO/2024/087729A1 |
The present invention relates to the technical field of microbial fermentation, and in particular, to an Escherichia coli mutant strain HCYJ-03 for producing polysialic acid and a use. The Escherichia coli mutant strain HCYJ-03 is named ...
|
|
WO/2024/092165A1 |
Disclosed herein is a method for diagnosing a mycobacterial infection in a subject. The method comprises performing acetonitrile fractionation of a subject sample to deplete depleted in high molecular weight proteins. The sample is enzym...
|
|
WO/2024/089645A1 |
The present disclosure concerns a method of obtaining a composition having yeast proteins derived from yeast protoplasts The present disclosure also includes compositions comprising yeast proteins derived from yeast protoplasts, edible p...
|
|
WO/2024/086963A1 |
Provided is a composition for use in preventing or minimizing exercise-induced muscle damage (EIMD) in a subject in need thereof. The composition includes Lactobacillus paracasei PS23 and a carrier thereof. Also provided is a method of p...
|
|
WO/2024/087539A1 |
An enhanced StayGold yellow fluorescent protein and the use thereof, which relate to the technical field of recombinant proteins. With regard to the enhanced StayGold yellow fluorescent protein, the amino acid sequence of StayGold compri...
|
|
WO/2024/088087A1 |
The present invention relates to the field of medical biology, and specifically to expression of a human papillomavirus (HPV) 68 L1 protein, and virus-like particles (VLPs) and a preparation method therefor. The amino acid sequence of th...
|
|
WO/2024/090577A1 |
Provided are an animal cell culturing method and a technology related thereto. In the present invention, animal cells are cultured in the presence of a pea-derived material and/or a yeast extract.
|
|
WO/2024/085482A1 |
The present invention relates to a novel Metarhizium pinghaense 15R strain with insecticidal and bactericidal activity, and a use thereof. Specifically, the present invention relates to a novel Metarhizium pinghaense 15R strain that exhi...
|
|
WO/2024/083954A1 |
A method of processing spent brewer's yeast (BSY) to a fermented BSY product is described. The BSY product is a pleasant tasting, nutritious and functional ingredient which enables the ingredient to be used for human consumption in foods...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/083600A1 |
In the present invention new Bacillus strains are provided. More specifically, Bacillus strains having extracellular hydrolase activity and demonstrating reduced malodor after incubation for at least 5 days for at least 25 °C in a lacto...
|
|
WO/2024/084510A1 |
The present invention relates to a cost-effective process for the synthesis of hyper-production of poly gamma glutamic acid using L-glutamic acid independent approach. Specifically, the present invention relates to the synthesis of poly ...
|
|
WO/2024/084851A1 |
A plasmalogen production–promoting culture medium according to the present invention includes lactose as a carbon source and is to be used to culture lactic acid bacteria.
|
